Skip to main content
SpringerLink
Log in
Book cover

Triazenes pp 109–118Cite as

Clinical Use of Triazenes

  • Chapter

  • 45 Accesses

Abstract

Dacarbazin (5-methyl-(3,3-dimethyl-1-triazene,DTIC) is an alkylating agent with established clinical antitumour activity, As a single agent, DTIC explicits tumour inhibitory effect against Hodgkin’s disease, melanoma and sarcomas. Certain apudomas may be also responsive to DTIC. As a results of these observations various combination regimens containing DTIC were designed and proved to be clinically effective. This paper is aimed at summarizing the clinical results of DTIC treatment so far achieved in various malignant diseases.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. R.L.Comis, DTIC (NSC-45388) in Malignant Melanoma: A Perspective. Cancer Treatment Rep.60: 165 (1976).

    CAS  Google Scholar 

  2. T.H.Wassermann, M.Slavik, S.K.Carter, Clinical comparison of the Nitrosoureas. Cancer 36: 1258 (1975)

    Article  Google Scholar 

  3. H. O.Peters, J.Becker, V.Lins, D.Preding, Eldisine (vindesin) in der Chemotherapie solider Tumoren und Hemoblastosen, in: “Spezielle Tumorchemotherapie”, S. Tanneberger, et., Akademie Verlag, Berlin, 1986, 334.

    Google Scholar 

  4. J.K.Luce, Chemotherapy and Malignant Melanoma. Cancer 30: 16o4 (1974)

    Google Scholar 

  5. M.J.Mastrangelo, A.R.Baker, H.R.Katz, Cutaneous Melanoma In: V.T. De Vita, S. Hellman, S.A. Rosenberg, “Cancer, Principles and Practice of Oncology”. J.P.Lippincott Company, Philadelphia, 1985. 1371.

    Google Scholar 

  6. C.A.Presant, A.Bartolucci, C.Balch, M.Tronier, A Randomized Comparison of Cyclophosphamide, DTIC with or without Piperazinedione in Metastatic Malignant Melanoma. Cancer 49: 1355 (1982).

    Article  PubMed  CAS  Google Scholar 

  7. P.P.Carbone, W.Costello, Eastern Cooperative Group Studies with DTIC (NSC-45388). Cancer Treatment Rep. 60: 193 (1976).

    CAS  Google Scholar 

  8. D.L.Ahmann, H.F.Bisel, J.H.Edmonson, R.G.Hahn, R.T.Eagan, M.J. O’Connel, S.Frytak, Clinical Comparison of Adriamycin and a Combination of methyl-CCNU and Imidazole Carboxamide in Disseminated Malignant Melanoma. Clin.Pharmacol.Therap. 19: 821 (1976).

    CAS  Google Scholar 

  9. R.E.Gemer, G.E.Moore, M.S.Didolkar, Chemotherapy of Disseminated Malignant Melanoma with Dimethyl Triazeno Imidazole Carboxamide and Dactinomycin Cancer 32: 755 (1973).

    Google Scholar 

  10. L.H.Einhorn, M.A.Burgess, C.Vallejos, P.Bodey, J.V.Guttermann, G.Mavligit, E.M. Hersh J.K.Luce, E.Frei, E.J.Freireich, J.A.Gottlieb, Prognostic Correlations and Response to Treatment in Advanced Metastatic Malignant Melanoma, Cancer Res. 34: 1995 (1974).

    PubMed  CAS  Google Scholar 

  11. B.S.Yap, M.A.Burgess, R.S.Benjamin, E.M.Hersh, G.P.Bodey, DTIC and Continuous 5-day Infusion of Vindesine+i.v.MER for Metastatic Melanoma — ASCO abstracts 1: 178 (1982).

    Google Scholar 

  12. J.J.Costanzi, DTIC (NSC-45388) studies in Southwest Oncology Group. Cancer Treatment Rep., 60: 189 (1976).

    CAS  Google Scholar 

  13. G.Beretta, G.Bonadonna, N.Cascinelli, Comparative Evaluation of Three Combination Regimes for Advanced Malignant Melanoma: Results of an International Cooperative Study. Cancer Treatment Rep., 60: 33 (1976).

    CAS  Google Scholar 

  14. M.Graubner, G.Staebe, J.Illig, E.Paul, M.Hundeiker, H.Pralle, Cisplatin-Vindesine-Dacarbazine in Advanced Melanoma: Response Related to Site of Metastases. J.Cancer Res. Clin.Oncol. 107: 62 (1984).

    Google Scholar 

  15. H.F.Seigler, V.S.Lucas, N.J.Pikkett, A.T.Huang, DTIC, CCNU, Bleomycin and Vincristine (BOLD) in Metastatic Melanoma. Cancer 46: 2346 (1980).

    Article  PubMed  CAS  Google Scholar 

  16. S.Somfai-Relle, L.Németh, Antitumour Effect of DBD in Vivo. In:“Dibromodulcitol”, S. Eckhardt ed., Medicina, Budapest, 1982, 73

    Google Scholar 

  17. R.P.Richman, T. H.Woodcock, T.T.Kubota, M.S.Blumenreich, P.S.Gentile, J.C.Allegra, Phase II Trial of Vinblastine, Bleomycin and Cisplatin (VBP) Followed by Dacarbazine and Mitolactol in Metastatic Melanoma. Cancer Treat.Rep. 68: 1395 (1984).

    PubMed  CAS  Google Scholar 

  18. M.K.Samson, C.D.Haas, L.H.Baker, G.Cummings, Dibromodulcitol (DBD), DTIC and Actinomycin-D in Disseminated Malignant Melanoma. A Phase I–II Clinical Trial. Am.J.Clin.Oncol. 8: 167 (1985).

    Article  PubMed  CAS  Google Scholar 

  19. A.Kiskőszegi, DBD Containing combinations in Melanoma. In: Institóris L., Kaczmarek J., Jeney, A., “Mitolactol” Bibliotheca Chinoina, Budapest, Hungary, 1986, 84.

    Google Scholar 

  20. E.Frei, III: Status and Perspectives in Chemotherapy of Hodgkin’s Disease. Arch.Int.Med. 131: 439 (1973).

    Article  Google Scholar 

  21. G.Bonadonna, R.Zucali, S.Monfardini, M.Delena, C.Uslenghi, Combination Chemotherapy of Hodgkin’s Disease with Adriamycin, Bleomycin, Vinblastine and Imidazole Carboxamide Versus MOPP, Cancer 35: 252, 1975.

    Article  Google Scholar 

  22. A.Santoro, V.Bonfante, G.Bonadonna: Salvage Chemotherapy with ABVD in MOPP-resistant Hodgkin’s Disease. Ann. Intern.Med. 96: 139, 1982.

    PubMed  CAS  Google Scholar 

  23. N.Taunir, F.Hagemeister, W.Velasquez, Long-term Follow-up with ABDIC Salvage Chemotherapy of MOPP Resistant Hodgkin’s Disease. J.Clin.Oncol. 1: 432 (1983).

    Google Scholar 

  24. L.H.Einhorn, S.D.Williams, E.E.Stevens: The Treatment of MOPP-Refractory Hodgkin’s Disease with Vinblastine, Doxorubicin, Bleomycin, CCNU and Dacarbazine, Cancer 51: 1348 (1983).

    Article  PubMed  CAS  Google Scholar 

  25. G.Bonadonna, P.Valagussa, A.Santoro, Alternating Non-cross Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin’s Disease. A report of 8-year Results. Ann.Intern.Med. 104: 739 (1986).

    PubMed  CAS  Google Scholar 

  26. J.E.Gottlieb, R.S.Benjamin, L.H.Baker, Role of DTIC (NSC-45388) in the Chemotherapy5 of Sarcomas. Cancer Treatm.Rep. 60: 199 (1976).

    CAS  Google Scholar 

  27. S.A.Rosenberg, H.D.Suit, L.H.Baker, Sarcomas of Soft Tissues In: V.T.DeVita, S.Hellman, S.Rosenberg, “Cancer Principles and Practice of Oncology”, Lippincott, Philadelphia, 1985, 1281.

    Google Scholar 

  28. E.C. Borden, D. Amato, H.T. Enterline, H. Lerner, P.P. Carbone, Randomized Comparison of Adriamycin Regimens for Treatment of Metastatic Soft Tissue Sarcomas. Proc.AACR and ASCO, C-902, 1983.

    Google Scholar 

  29. J.E. Gottlieb, L.H. Baker, J.M. Quagliana, Chemotherapy of Sarcomas with a Combination of Adriamycin and DTIC. Cancer 30: 1632, (1972).

    Article  PubMed  CAS  Google Scholar 

  30. J.E. Gottlieb, L.H. Baker, M.A. Burgess, Sarcoma Chemotherapy. In: Cancer Chemotherapy. Fundamental Concepts and Recent Advances. 19th Ann.Clin.Conf. in Cancer, 1974, Year Book Medical Publishers. 1975.

    Google Scholar 

  31. E.T.Creagan, R.G.Hahn, D.L.Ahmann, A Comparative Clinical Trial Evaluating the Combination of Adriamycin, DTIC and Vinblastine, the Combination of Actinomycin D and Cyclophosphamide for advanced sarcoma. Cancer Treatm.Rep. 60: 1385 (1976).

    CAS  Google Scholar 

  32. H.M.Pinedo, C.P.J.Vendrik, V.H.C.Bramwell, Reevaluation of the CYVADIC Regimen for Metastatic Soft Tissue Sarcoma, Pro.AACR and ASCO C-228, 1979.

    Google Scholar 

  33. B.Yap, L.H.Baker, J.G.Sinkovics, Cyclophosphamide, Vincristine, Adriamycin and DTIC (CYVADIC) Combination Chemotherapy for the Treatment of Advanced Sarcomas. Cancer Treatm. Rep. 64: 93 (1980).

    CAS  Google Scholar 

  34. R.S.Benjamin, J.A Gottlieb, L.H.Baker, CYVADIC Versus CYVADACT. A Randomized Trial of Cyclophosphamide (CY), Vincristine (V) and Adriamycin (A) plus either Dacarbazin (DIC) or Actinomycin D (DACT) in Metastatic Sarcomas. Proc.AACR and ASCO C-256, 1976.

    Google Scholar 

  35. H.Pinedo, Y.Kenis, Chemotherapy of Advanced Soft Tissue Sarcomas in Adults. Cancer Treat.Rev. 4: 67 (1977).

    Article  PubMed  CAS  Google Scholar 

  36. G.A.Omura, F.J.Major, J.A.Blessing, T.V.Sedlacek, J.T.Thigpen, W.T.Creasman, R.J.Zino, A randomized study of Adriamycin with or without Dimethyltriazenoimidazole Carboxamide in Advanced Uterine Sarcomas. Cancer 52: 626 (1983)

    Article  PubMed  CAS  Google Scholar 

  37. F.Aziza, J.Bitran, G.Javehari, A.L.Herbst, Remission of Uterine Leiomyosarcomas Treated with Vincristine, Adriamycin and Dimethytriazenoimidazolecarboxamide. Ann.J.Obstet.Gynecol. 133: 379 (1979).

    Google Scholar 

  38. T.Vietti, Metastatic Ewing, Med.Pediat.Oncol. 7: 61 (1979)

    Google Scholar 

  39. W.W.Sutow, Multidrug Chemotherapy in Osteosarcoma.Clin.Drthop. 153: 67 (1980)

    Google Scholar 

  40. W.W.Sutow, M.P.Sullivan, D.J.Fernbach, Adjuvant Chemotherapy in Primary Treatment of Osteogenic Sarcoma. Cancer 36: 1598 (1975)

    Article  PubMed  CAS  Google Scholar 

  41. M.Carli, A.A.Green, F.A.Hayes, Therapeutic Efficacy of Single Drugs for Childhood Neuroblastoma: A review In: “Pediatric Oncology” Excerpta Medica, Amsterdam, Oxford, Princeton, 1982, 141.

    Google Scholar 

  42. M.Carli, G.Pastore, G.Perilongo, L.Zanesco, The Role of Chemotherapy in Neuroblastoma. In: “Pediatric Oncology”, Excerpta Medica, Amsterdam, Oxford, Princeton, 1982, 151.

    Google Scholar 

  43. J.Z.Finklestein, M.F.Klemperer, A.Evans: Multiagent Chemotherapy for Children with metastatic Neuroblastoma. A report from CCSG Med.Pediatr.Oncol. 6: 179 (1979).

    Article  CAS  Google Scholar 

  44. D.Traggis, N.Jaffe, D.Nathan, Advanced Neuroblastoma; Treatment with Combination Chemotherapy: Vincristine, Adriamycin, Nitrogen Mustard and DTIC (VAM-DTIC) Proc.Amer.Ass.Cancer Res. 17: 140 (1976).

    Google Scholar 

  45. T.H.Wassermann, R.L.Comis, M.Goldsmith, H.Handelsmann, J.S.Penta, M.Slavik, W.T.Soper, S.K.Carter, Tabular Analysis of the Clinical Chemotherapy of Solid Tumours. Cancer Chemother. Rep. 6: 399 (1975).

    Google Scholar 

  46. N.J.Perevodcsikova, M.B.Büchkov, G.A.Tevzadze, Intensive Combination Chemotherapy combined with radiotherapy in the Treatment of Small Cell Lung Cancer (in Russian). Vestnik AMN SSSR 7: 60 (1981).

    Google Scholar 

  47. C.G.Moertel, Treatment of the Carcinoid tumour and the Malignant Carcinoid Syndrome. J. Clin. Oncol. 1: 727 (1983).

    PubMed  CAS  Google Scholar 

  48. A.Kessinger, J.F.Foley, H.M.Lemon, Use of DTIC in the Malignant Carcinoid Syndrome. Cancer Treatm. Rep. 61: 1o1 (1977).

    Google Scholar 

  49. J.F.Foley, H.M.Lemon, DTIC Therapy for Malignant Islet Cell Tumours. Proc. ASCO 1: 169 (1982)

    Google Scholar 

  50. A.Kessinger, H.M.Lemon, J.F.Foley, The Glucagonoma and its Management. J. Surg. Oncol. 9: 419 (1977).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Oncology, Budapest, Hungary

    Sándor Eckhardt

Authors
  1. Sándor Eckhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Istituto di Farmacologia, Università di Trieste, 34127, Trieste, Italy

    Tullio Giraldi

  2. Toxicology Unit, Medical Research Council, Woodmansterne Road, SM5 4EF, Carshalton, Surrey, UK

    Thomas A. Connors

  3. Divisione di Oncologia Medica, Ospedale S. Maria della Misericordia, 33100, Udine, Italy

    Giuseppe Cartei

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media New York

About this chapter

Cite this chapter

Eckhardt, S. (1990). Clinical Use of Triazenes. In: Giraldi, T., Connors, T.A., Cartei, G. (eds) Triazenes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3832-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3832-5_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6710-9

  • Online ISBN: 978-1-4615-3832-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation